Direxion Daily S&P Biotech Bull 3X ETF
LABU
19 hedge funds and large institutions have $24.5M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 6 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
114% more capital invested
Capital invested by funds: $11.4M → $24.5M (+$13M)
0.14% more ownership
Funds ownership: 0.31% → 0.45% (+0.14%)
10% less funds holding
Funds holding: 21 → 19 (-2)
23% less call options, than puts
Call options by funds: $9.88M | Put options by funds: $12.8M
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HJMC
Hellman Jordan Management Company
Quincy,
Massachusetts
|
+$6.26M |
| 2 |
Jane Street
New York
|
+$5.16M |
| 3 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$1.11M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$745K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$928K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$616K |
| 3 |
VF
Virtu Financial
New York
|
-$519K |
| 4 |
FMA
FNY Managed Accounts
New York
|
-$274K |
| 5 |
CCS
Crosspoint Capital Strategies
Orinda,
California
|
-$82K |
LABU Hedge Fund Activity: Q2 2016 in Review
19 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2016, worth a combined $24.5M — up 114% from $11.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LABU and 4 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 11 added.
The largest buyer was Hellman Jordan Management Company, opening a new position worth an estimated $6.26M. The largest seller was Tower Research Capital (TRC), cutting an estimated $928K.
- 19 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2016, down from 21 in Q1 2016.
- Funds reported $24.5M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2016, up 114% quarter-over-quarter.
- 4 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2016 and 6 closed out, a net change of -2 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2016 was Hellman Jordan Management Company, an estimated $6.26M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q2 2016 was Tower Research Capital (TRC), an estimated $928K sold.
Based on aggregated 13F filings for Q2 2016.